Vanberra Signal

BillionToOne

Curated by Signal

Provider of cell-free cancer liquid biopsy test

Overview

Provider of cell-free cancer liquid biopsy test. The company provides a molecular counter platform to count the DNA molecules from blood samples. It provides genetic tests for cystic fibrosis, spinal muscular atrophy, sickle cell disease, etc.

Key facts

Founded
2015

Business model

Contact

Open roles

305 roles
  • Account Executive

    Buffalo, NY · On-site · Volunteer

  • Account Executive

    Harrisburg, PA · On-site · Volunteer

  • Prenatal Account Executive

    Pittsburgh, PA · On-site · Volunteer

+ 302 more open roles on Signal

More on Vanberra Signal

Members only

Competitors & similar companies

More Life Sciences Technology companies
  • Provider of regulatory compliance consulting services

    Life Sciences TechnologyColumbia, United States
  • Developing an oximeter for real-time monitoring of cellular oxygenation and perfusion

    Life Sciences TechnologySeattle, United States
  • Developer of cervical cancer screening device

    Life Sciences TechnologyMcallen, United States

About BillionToOne

What does BillionToOne do?

Provider of cell-free cancer liquid biopsy test.

Where is BillionToOne headquartered?

BillionToOne is headquartered in San Francisco, United States.

When was BillionToOne founded?

BillionToOne was founded in 2015.

Which sector is BillionToOne in?

BillionToOne operates in Life Sciences Technology.

Who are BillionToOne's competitors?

Companies similar to BillionToOne include Advarra, Opticyte, and Hera Diagnostics.

Is BillionToOne hiring?

Yes. BillionToOne has 305 open roles listed on Vanberra Signal.